Palmar plantar erythrodysesthesia primary prevention
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia primary prevention On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia primary prevention |
|
Palmar plantar erythrodysesthesia primary prevention in the news |
|
Blogs on Palmar plantar erythrodysesthesia primary prevention |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
Overview
Avoiding excessive manual work and walking, wound care to prevent infection, limb elevation, cold compresses, avoiding extreme temperatures, analgesics, creams and emollients are suggested to prevent, delay onset, and/or decrease the severity of PPE.
Primary prevention
A number of measures have been suggested to prevent, delay onset and/or decrease the severity of PPE. General measures include:[1] [2] [3] [4]
- Avoiding excessive manual work and walking, to prevent excessive pressure or friction to the skin
- Wound care to prevent infection
- Limb elevation to reduce edema
- Cold compresses
- Avoiding extreme temperatures
- Analgesics
- Creams and emollients
References
- ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ Susser WS, Whitaker-Worth DL, Grant-Kels JM (1999). "Mucocutaneous reactions to chemotherapy". J Am Acad Dermatol. 40 (3): 367–98, quiz 399-400. PMID 10071309.
- ↑ Lassere Y, Hoff P (2004). "Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)". Eur J Oncol Nurs. 8 Suppl 1: S31–40. doi:10.1016/j.ejon.2004.06.007. PMID 15341880.
- ↑ Gerbrecht BM (2003). "Current Canadian experience with capecitabine: partnering with patients to optimize therapy". Cancer Nurs. 26 (2): 161–7. PMID 12660565.